AstraZeneca PLC ADR AZN
News
France Secures Billions at Foreign Investment Summit
AstraZeneca withdraws COVID-19 vaccine
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
Astrazeneca on Track for Record High Close — Data Talk
Astrazeneca on Track for Record High Close — Data Talk
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
Astrazeneca Up Nearly 6%, on Pace for Largest Percent Increase Since November 2022 — Data Talk
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AstraZeneca Earnings, Sales Rise, Beating Forecasts — Update
AstraZeneca Earnings, Sales Rise, Beat Forecasts
Q1 2024 results
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
AstraZeneca Raises Dividend
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors